CAMBRIDGE, Mass., July 29,
2024 /PRNewswire/ -- Akebia Therapeutics®,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease,
today announced participation in two investor conferences in
August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG)
44th Annual Growth Conference, August 13-14, 2024 in Boston.
- BTIG Biotechnology Conference
John Butler, Chief Executive Officer, will
participate in a fireside chat on Tuesday,
August 6, at 8:00 am EST.
- CG 44th Annual Growth Conference
Mr.
Butler will present on Wednesday, August
14 at 8:30 a.m. EST. A webcast of the presentation can
be accessed through the "Investors" section of Akebia's
website at https://ir.akebia.com following
the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website
at www.akebia.com, which does not form a part of
this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-upcoming-investor-conferences-302208267.html
SOURCE Akebia Therapeutics, Inc.
